Novosti
Khirurgii

 This journal is
indexed in Scopus
journal cover
android icon Android Applicaion

Year 2012 Vol. 20 No 6

LECTURES, REVIEWS

A.G.SALMANOV1, A.K.TOLSTANOV 2, V.F.MARIEVSKI 3, V.V. BOYKO 4, I.A.TARABAN 5

EPIDEMIOLOGICAL SURVEILLANCE FOR RESISTANCE TO ANTIMICROBIAL PREPARATIONS

State sanitary-epidemiological department of the Ukraine 1 ,
Ministry of healthcare of the Ukraine 2 ,
SE “Institute of epidemiology and infectious diseases named after L.V.Gromashevsky of NAMS of the Ukraine” 3 ,
SE “Institute of general and urgent surgery of NAMS of the Ukraine” 4,
Kharkov National Medical University 5,
The Ukraine

Increasing concern about the emergence of resistance of the clinically important pathogens has led to the establishment of a number of surveillance programmes to monitor the actual extent of resistance at the local, regional and national levels. This review describes some of the major programs of surveillance initiatives and the ways to apply the obtained data in different settings. In the hospital, surveillance data are used to monitor local antibiograms resistance and to determine infection control strategies and antibiotic usage policies. The surveillance data are used to monitor public health threats such as infectious disease outbreaks involving resistant pathogens and the effects of bioterrorism countermeasures by following the effects of prophylactic use of different antibiotics on resistance. Initially, the pharmaceutical industry sponsored surveillance programmes to monitor the susceptibility of clinical isolates to marketed antibiotic products. However, at present, in the era of burgeoning resistance, many developers of antimicrobial agents find surveillance data useful for defining new drug discovery and development strategies, in that they assist with the identification of new medical needs, allow modelling of future resistance trends, and identify high-profile isolates for screening the activity of new agents. Surveillance data also represent an integral component of regulatory submissions for new agents and, together with clinical trial data, are used to determine breakpoints. It is clear that antibiotic resistance surveillance systems will continue to provide valuable data to health care providers, university researchers, pharmaceutical companies and the government.

Keywords: antibiotic resistance, epidemiological surveillance, nosocomial infectionss
p. 93 – 101 of the original issue
References
  1. Vsemirnaia Organizatsiia Zdravookhraneniia. Global'naia strategiia VOZ po sderzhivaniiu ustoichivosti k protivomikrobnym preparatam [WHO global strategy for containment of antimicrobial resistance]. 2001. rezhim dostupu: http://www.who.int/drugresistance/WHO_Global_Strategy.htm/ru/
  2. Salmanov AG. Kh³rurg³chn³ ³nfekts³¿ [Surgical infections]: monograf³ia. Kiev, Ukraina: Kondor; 2011. 374 p.
  3. Salmanov AG, Mar³ºvs'kii VF, Boiko VV, ²offe ²V, Taraban ²A. Antib³otikorezistentn³st' v kh³rurg³¿ [Antibiotic resistance in surgery] . Khar'kov, Ukraina: NTMT. 2012. 456 p.
  4. Salmanov AG, Mar³ºvs'kii VF. ²nfekts³inii kontrol' v kh³rurg³¿ [Infection control in surgery]: Monograf³ia. Kiev, Ukraina: N³ka-Tsentr; 2011. 269 p.
  5. Salmanov AG. Mar³ºvs'kii VF, Nalapko Iu². Anal³z et³olog³¿ ³ antib³otikorezistentnost³ osnovnikh zbudnik³v vnutr³shn'ol³karnianikh ³nfekts³i u kh³rurg³chnikh stats³onarakh [Analysis of etiology and antibiotic resistance of the main pathogens of nosocomial infections in surgical hospitals]. Ukr Zhurn Ekstr Med ³m GO Mozhaºva. 2010;(3):48–55.
  6. Salmanov AG, Mar³ºvs'kii VF, Doan S². Antib³otikorezistentn³st' nozokom³al'nikh shtam³v Escherichia coli v kh³rurg³chnikh stats³onarakh Ukra¿ni v 2008 r [Antibiotic resistance of nosocomial strains of Escherichia coli in Ukrainian surgical hospitals in 2008 yr]. Kh³rurg³ia Ukra¿ni. 2010;(4):78–83.
  7. Salmanov AG, Lazorishchinets' VV, Mar³ºvs'kii VF. Antib³otikorezistentn³st' kl³n³chnikh shtam³v Staphylococcus aureus v kh³rurg³chnikh stats³onarakh Ukra¿n³ v 2010 r. [Antibiotic resistance of clinical strains of Staphylococcus aureus in Ukrainian surgical hospitals in 2010 yr]. Kh³rurg³ia Ukra¿ni. 2011(3):26–31.
  8. Salmanov AG, Mar³ºvs'kii VF, Doan S². Antib³otikorezistentn³st' nozokom³al'nikh shtam³v Enterococcus faecalis v kh³rurg³chnikh stats³onarakh Ukra¿ni u 2008 r. [Antibiotic resistance of nosocomial strains of Enterococcus faecalis in Ukrainian surgical hospitals in 2008 yr]. Ukr Neirokh³rurg Zhurn. 2010. ¹4:61–67.
  9. Salmanov AG, Mar³ºvs'kii VF, Doan S². Antib³otikorezistentn³st' nozokom³al'nikh shtam³v Enterobacter spp. v kh³rurg³chnikh stats³onarakh Ukra¿n³ v 2009 r [Antibiotic resistance of nosocomial strains of Enterobacter spp in Ukrainian surgical hospitals in 2009 yr]. S³meina Meditsina. 2010;(4):95–100.
  10. Salmanov AG, Mar³ºvs'kii VF, Doan S². Antib³otikorezistentn³st' nozokom³al'nikh shtam³v Pseudomonas aeruginosa v kh³rurg³chnikh stats³onarakh Ukra¿ni v 2008 r. [Antibiotic resistance of nosocomial strains of Pseudomonas aeruginosa in Ukrainian surgical hospitalsin 2008 yr]. Shpital'na Kh³rurg³ia. 2010(3):86–89
  11. Salmanov AG, Mar³ºvs'kii VF, Doan S². Antib³otikorezistentn³st' osnovnikh zbudnik³v kh³rurg³chnikh ³nfekts³i [Antibiotic resistance of major causative agents of surgical infections]. Zb³rnik naukovikh prats' golovnogo v³is'kovo-medichnogo kl³n³chnogo tsentru «GVKG» MO Ukra¿ni. Ki¿v, Ukraina; 2010(Vip 16):391–98.
  12. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2010. Stockholm, Sweden: ECDC; 2010. Available from: http://ecdc.europa.eu/en/publications/Publications.
  13. European Centre for Disease Prevention and Control. Surveillance of surgical site infections in Europe, 2008–2009. Stockholm, Sweden: ECDC; 2012. Available from: http://www.ecdc.europa.eu/en/publications/Publications.
  14. World Health Organization. The evolving threat of antimicrobial resistance – Options for action. Geneva, Switzerland; 2012. Available from: http://www.who.int/patientsafety/implementation/amr/publication/en/.
  15. Masterton RG. Surveillance studies: how can they help the management of infection? J Antimicrob Chemother. 2000;46(Topic T2):53–58.
  16. Karlowsky JA, Sahm DF. Antibiotic resistance - is resistance detected by surveillance relevant to predicting resistance in the clinical setting? Curr Opin Pharmacol. 2002 Oct;2(5):487–92.
  17. Goldmann DA, Weinstein RA, Wenzel RP, Tablan OC, Duma RJ, Gaynes RP, Schlosser J, Martone WJ. Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership. JAMA. 1996 Jan 17;275(3):234–40.
  18. Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, Eckman MR, Farrer WE, Greene WH, Lorian V, Levy S, McGowan JE Jr, Paul SM, Ruskin J, Tenover FC, Watanakunakorn C. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis. 1997 Sep;25(3):584–99. Review.
  19. Schuchat A, Hilger T, Zell E, Farley MM, Reingold A, Harrison L, Lefkowitz L, Danila R, Stefonek K, Barrett N, Morse D, Pinner R. Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis. 2001 Jan-Feb;7(1):92–9.
  20. Felmingham D, Gruneberg RN. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother. 2000 Feb;45(2):191–203.
  21. Pfaller MA, Jones RN, Biedenbach DJ. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn Microbiol Infect Dis. 2001 Dec;41(4):177–82.
  22. Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother. 2000 Mar;44(3):747–51.
  23. Thornsberry C, Jones ME, Hickey ML, Mauriz Y, Kahn J, Sahm DF. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. J Antimicrob Chemother. 1999 Dec;44(6):749–59.
  24. Thornsberry C, Sahm DF, Kelly LJ, Critchley IA, Jones ME, Evangelista AT, Karlowsky JA. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis. 2002 Mar 1;34(Suppl 1):S4–S16.
  25. Sefton AM. Mechanisms of antimicrobial resistance: their clinical relevance in the new millennium. Drugs. 2002;62(4):557–66.
  26. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, Schuchat A; Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000 Dec 28;343(26):1917–24.
  27. Hashimoto H. Drug resistance of methicillin-resistant Staphylococcus aureus (MRSA) in Japan until 1993. Jpn J Antibiot. 1994 Jun;47(6):575–84. [Article in Japanese]
  28. Jones ME, Mayfield DC, Thornsberry C, Karlowsky JA, Sahm DF, Peterson D. Prevalence of oxacillin resistance in Staphylococcus aureus among inpatients and outpatients in the United States during 2000. Antimicrob Agents Chemother. 2002 Sep;46(9):3104–5.
  29. Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, Hancock GA, O'Hara CM, McAllister SK, Clark NC, Hiramatsu K. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol. 1998 Apr;36(4):1020–27.
  30. Lipsitch M, Samore MH. Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis. 2002 Apr;8(4):347–54.
  31. Sahm DF, Karlowsky JA, Kelly LJ, Critchley IA, Jones ME, Thornsberry C, Mauriz Y, Kahn J. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob Agents Chemother. 2001 Apr;45(4):1037–42.
Address for correspondence:
01601, Ukraina, g. Kiev, ul. Grushevskogo, d. 7, Gosudarstvennaya sanitarno- epidemiologicheskaya sluzhba Ukrainyi,
e-mail: moz.sag@bigmir.net,
Salmanov Aydyin Gurbanovich
Information about the authors:
Salmanov A.G. Candidate of medical sciences, chief specialist of the State sanitary-epidemiological department of the Ukraine
Tolstanov A.K. Doctor of medical sciences, deputy minister of the Ministry of Healthcare of the Ukraine
Marievski V.F. Doctor of medical sciences, professor, director of SE “Institute of epidemiology and infectious diseases named after L.V.Gromashevsky of NAMS of the Ukraine”
Boyko V.V. Doctor of medical sciences, professor, director of SE “Institute of General and Urgent Surgery of NAMS of the Ukraine”
Taraban I.A. Doctor of medical sciences, professor, professor of the surgery chair ¹1 of Kharkov National Medical University
Contacts | ©Vitebsk State Medical University, 2007-2023